research on india_healthcare sector in india monthly update_february 2012

Healthcare Sector in India Monthly Update

February 2012

Top Story Therapeutic cancer vaccine to go for human clinical trials soon The cancer vaccine molecule that is expected to be a significant treatment for breast, ovarian, cervical, thyroid and blood cancer will pave its way to final phase of clinical trial soon after it gets clearance from Drug Controller General of India (DCGI). The clinical trial will be conducted at Cancer Institute (WIA) Adyar in Chennai with 18 patients currently in their 3rd stage of cervical cancer. USA based Memorial Sloan‐Kettering Cancer Centre will also participate in the trial under an agreement between NII and the National Cancer Institute under the US government's National Institutes of Health (NIH) and will focus on ovarian cancer.The molecule was invented by National Institute of Immunology (NII) under the supervision of Department of Biotechnology. The vaccine has already been successful on rodents using different cancer cell lines. The vaccine involves Dendritic Cell Therapy wherein a patient’s own immune cells are used to fight cancer. The therapy involves extracting the blood cells from the patient’s body and processing in the laboratory to produce dendritic cells in large numbers which are otherwise present in human bodies in small quantity. News Update

General Norwich Clinical Services receives approval from India Drugs Controller America based Norwich Clinical Services has announced its expansion in the clinical research facility. It has also inaugurated its Phase I – III clinical trials facility that includes pharmacokinetics in healthy volunteers, bio‐availability and bio‐equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies. The facility has received green signal from the Drugs Controller General of India due o their intricate adherence to GCP, GLP, CFR part 11 and other applicable regulatory equirements. tr India to teach Laproscopy to Tanzania Mumbai based Joy Hospital in an attempt to make medical technology accessible to poor even in the most backward countries has planned to offer Tanzania based surgeons’ free training in Laproscopy. Tanzania based Mission Mikocheni hospital is soon to invest on the equipments and will send a surgeon to India to learn the technique. While the Tanzanian surgeons come to India to learn the technique, the Joy Ram Hospital doctors will visit their country to ensure that surgeons are being able to carry out the Laproscopy without any hindrance.

Healthcare – Monthly Update

ill now the hospital has provided such training to 800 surgeons all over the world ocusing on Asian countries.


Tf Celon Laboratories’ new manufacturing unit to be complete by March 2012 Bio‐pharmaceutical company Celon Laboratories Ltd. will soon have its new manufacturing facility at Kolthur Village near the Genome Valley located at the outskirts of Hyderabad spread over 11 acres. The unit is worth INR 1200 mn which is expected to be complete by March 2012. The new facility is being set up with the purpose of producing hormonal products and will be focusing on US and European markets. Celon specializes in oncology, critical care, gynecology, urology and nephrology related drugs and has diversified into ntibiotics, pain management, gastro‐intestinal, cough & cold and nutraceutical drugs ith its Healon multi speciality division.

aw Jubilant Biosys td. and Endo Pharmaceuticals collaboration brings early news of success of their cancer treating molecule Jubilant Biosys Ltd. announced their successful early stage milestone in its collaboration programme with Endo Pharmaceuticals that has nominated a candidate into full development. The newly discovered cancer targeting molecule is expected to

L

go for clinical trials by the end of 2012. The collaboration had begun 3 years back with the aim to focus on the unmet treatment needs of cancer. Bengaluru based Jubiliant Biosys Ltd. is a subsidiary of Noida based Jubiliant Life Sciences Ltd. Jubiliant Biosys specializes in integrated drug discovery and in development of solutions in the fields of Oncology, CNS and CVMED for serving the lobal pharmaceutical industry requirements. Endo Pharmaceuticals is a U.S.‐based ealthcare solution providing company. gh Curcumin proves beneficial in malaria treatment The pre human clinical trial of Curcumin has showed positive results in malaria treatment. The clinical trial has shown 100% cure rate on animals. Curcumin is the principal curcuminoid that gives turmeric its yellow colour. The study has been conducted by the Indian Institute of Science (IIS), Bangalore scientists. Curcumin in combination with anti‐malarial drug Artemisinins has been found to be effective in killing the malaria parasite and also prepare the immune system against recurrence of the disease. The IIS team ecstatic with their discovery is now preparing for human clinical trials of artemisinin‐curcumin combination therapy for treatment of both simple malaria cases and also the deadly cerebral malaria that kills 20% of patients. Sandrad launches unique helium less MRI equipment Mumbai based Sanrad Medical Systems has launched unique Helium less 1.5T superconducting MRI equipment. The recently developed 1.5T MRI system will require almost no helium in the entire span of 10 years‐ which is normally the

M eq o


lifespan of any RI uipment. The equipment based n Mitsubishi Magnet is also unique with the shortest bore length and a highly efficient Mitsubishi cold head. he equipment will be launched in two variants‐ the high end and basic versions hich will prove to be advantageous for both institutional and individual investors.

Tw IIL to develop vaccination for Chikungunya and JEV Hyderabad based Indian Immunologicals Limited (IIL) is making serious efforts to develop vaccinations against mosquito borne viruses Chikungunya and Japanese

tencephalitis virus (JEV). Both are in its pre clinical stage and is expected to s art clinical studies by 2012‐’13 with launch of the vaccination by 2014. IIL will be the first company in the world to have launched a vaccination for Chikungunya by using a virus strain isolated by a laboratory in the USA. In regard to JEV, IIL aims to develop a better and safer vaccination by producing the virus in cell culture, instead of using mouse brain for growing the virus, which is the prevalent method till date. Nanophotomedicine soon to become an effective remedy for cancer Nanophotomedicine, a solution for cancer ailing patients will be available in the market in the next 3‐4 years time. The solution was developed by a group of researchers in Kerela based Amrita Centre for Nanosciences and Molecular Medicine while its pre clinical evaluation was undertaken in Netherlands based Erasmus Medical Centre. The drug will soon go for its Phase I human clinical trial by Netherlands based pharmaceutical company Nano4therapy, which will also undertake commercialisation of the product. The medicine will be a revolutionary treatment for neuro‐endocrine tumours‐much more effective than currently available therapies. Once injected, the drug will accumulate in tumour tissues. Once it gets accumulated a low power laser light will be used to activate the nanomedicine and kill the cancerous cell. This innovative drug is non‐toxic and a biocompatible polymer that does not spread all over the body unlike he currently used radiation therapy which has possible side‐effect of spreading and amaging healthy cells. td Apollo and Medvarsity agreement to provide elearning solutions for Indian medical students Apollo Hospitals Group has entered into a pact with the New Zealand based software company Medvarsity Online Ltd. for distribution of online medical and allied health tutorials for Indian students. The software programmed by SIMTICS Ltd. will be distributed by Medvarsity in India. It will provide online modules for the related field of study to enable students study in detail and at their own pace. The online learning will also help students to be prepared with advanced aspects of medical science. This programme has been undertaken by Apollo Group specifically for meeting the ever growing medical personnels requirement in India.

Biosensors International comes to India Singapore based Biosensors International will feature in the India Live 2012 event organised in New Delhi by Cardiovascular Educational Research Trust. Biosensors has arranged for simulator for physicians for having an experience of its new Axxess™ self‐expanding bifurcation stent drug eluting system. With more than 1,000 interventional cardiologists of the SAARC nations to attend the conference, Biosensors expects to make a mark with their latest product. Biosensors currently operates in Singapore, Switzerland, China, the US, Japan, Indonesia, and the etherlands and with their latest product, Biosensors is planning to have a foothold in he Indian market as well. Nt Opto Circuits (India) Ltd. installs AEDs in Delhi Metro Stations In view of the regular occurrence of medical emergencies being witnessed by the Delhi Metro Rail Corporation (DMRC), Opto Circuits (India) Ltd. (OCIL) has installed the Automated External Defibrillators (AEDs) for free as part of their CSR. The AEDs have been installed in two of the busiest stations‐ Central Secretariat and Kashmere Gate till now. The portable electronic device can automatically diagnose and provide emergency medical care through defibrillation if a passenger suffers from a potentially life threatening cardiac arrest. The officials of DMRC and OCIL are in talks to install the equipment that costs etween INR 0.1‐0.2 mn in the rest of the metro stations, which can help in raising the hances of survival of such patients by 50%. bc Bokaro General Hospital certified to conduct neurosurgery course Bokaro General Hospital (BGH) reputed for its neurosurgery department has been recently approved to conduct super speciality DNB course on neurosurgery by the Diplomate of National Board (DNB). The neurosurgery team of BGH is known for having conducted as many as 300 surgeries in a year. Apart from already providing DNB courses in medicine, surgery, gynecology, anesthesia, radiology, pediatrics, bone and eye BGH now makes the addition of eurology in the stream of courses already on offer. Run by Bokaro Steel Plant, BGH is urrently in the process of restructuring the hospital into a medical college. nc Carestream makes its valued presence felt at 65th Indian Radiology Congress In the 65th Indian Radiology Congress organised by Indian Radiological & Imaging Association (IRIA) held in Hyderabad, Carestream Health India showcased its latest innovative products. The solutions were in field of Computed Radiography, Digital Radiography, Picture Archiving and Communication System and laser printing

e e p v solution. The equipments d vised ensur im ro ed imaging quality, faster accessibility to medical images and speedy work flow process. Carestream came to spotlight in the event with its 10 exhibited products which included CARESTREAM DRX‐ Ascend System, CARESTREAM DRX‐1 System,


CARESTREAM DRX‐Mobile Retrofit, CARESTREAM DirectView Classic CR System, CARESTREAM DirectView Vita CR System, CARESTREAM DryView 5700 Laser Imager, ARESTREAM DryView 6850 Laser Imager, CARESTREAM DryView CHROMA Imager, ARESTREAM Vue and Carestream Health.


CC Narayana Hrudayalaya Hospital featured in World’s 50 Most Innovative Companies New York based Fast Company that is recognised as the world’s progressive business media brand recently launched an editorial issue The World’s 50 Most Innovative Companies. The list included companies from varied genres like technology, internet, higher education, healthcare and fast food chains. Apart from big names that made to

the list, Bangalore based Narayana Hrudayalaya Hospital featured among the top 50innovative companies. Narayana Hrudayalaya featured in the list for its endeavour to bring low‐cost, high‐uality healthcare to more than a billion impoverished people in Southern India hrough its relentless focus on cutting costs and improving efficiencies. qt OmniActive establishes its R&D unit in Canada Mumbai based OmniActive Health Technologies has recently made an approximate investment of INR 74.05 mn to set up a R&D centre in Prince Edward Island (PEI) in Canada. It happens to be the first Indian company to have done so. It aims to conduct research in terms of biochemical pathways to produce anti‐ageing, womens' health or mens' health products. OmniActive chose PEI for its lucrative business offer that includes highly competitive business cost for investor companies, a positive tax environment, labour rebates, easy transition in terms of superior infrastructure and excellent business environment for a strong food‐agriculture sector. PEI also has a pool of skilled and educated labour orce, strategic infrastructure and provides convenient access to major markets for usiness purpose. fb News Update

Regulatory License renewal through SMS The Karnataka Drug Control Department (KDCD) has decided to revamp the procedure of issuing sales licenses to the pharmacy outlets of the state. KDCD seeks to provide the details on the clearance of applications submitted to seek fresh licenses or renewals via SMS to the state’s pharmacy outlet owners. Once the license would get cleared from the KDCD’s end, text messages would be sent to the owners. The text messaging service is expected to make the entire process fast and efficient. The state

d


has already identified and uploaded etails of 25500 pharmacy outlets spread across 30 districts of the state. he initiative has been supported by the state department of e‐governance and ational Informatics Centre (NIC) will be providing the required technical assistance.

TN Lack of funds fails Health Ministry to make BA/BE mandatory in CTRI Enormous efforts of the Union Ministry of Health to make registration of Bioavailability (BA) and Bioequivalence (BE) studies imperative with the Clinical Trial Registry of India (CTRI) has still not materialised. The Ministry had laid down the responsibility with the National Institute of Medical Statistics (NIMS) to carry out the required web network processing to incorporate the BA/BE features in the CTRI.

h s f However, the project a failed to be initiated as yet, with no unding coming from the Indian Council of Medical Research (ICMR). BA/BE studies help in finding out the Bioavailability and Bioequivalence of drugs especially for the generic and also for combination drugs. To acquire approval for a ew combination drug, BA/BE study results are essential to be submitted to the Drugs ontroller General of India. nC PIL filed by NGO brings illegal drugs trial under the scanner Swasthya Adhikar Manch a NGO has recently filed public interest litigation against illegal clinical trials of untested drugs on humans in India by multinational pharmaceutical companies. The Supreme Court has responded by issuing a notice to the Central Government and Medical Council of India to probe into the matter and come out with details of the same. It has been found that the inform consent is violated and the poor, mentally retarded, regnant ladies and children are often used for the clinical trials resulting in serious onsequences and even deaths of the subjects. pc RGSTC in plans to set up Biomedical Engineering and Technology Centre The Rajiv Gandhi Science and Technology Commission (RGSTC) in order to promote biomedical engineering and development of high quality but low cost medical devices are considering the setting up of Biomedical Engineering and Technology Centre (BETC). The RGSTC of the Maharashtra government is planning an initial investment

iof approximately INR 300 mn to INR 400 mn but is yet to f nalise the location of BETC which would be either in Mumbai or Nagpur. Research, engineering and development of indigenous monitoring, surgical aids, instruments, simple implants and prosthesis will be the key areas of concern. Along with these, BETC will also venture into bringing in low cost devices like artificial oints for the large number of patients who are unable to afford expensive imported evices. jd PanIndia code for ambulances soon

The government of India will soon introduce a common colour code, design and equipment for all ambulances across the country for advanced patient care during transit. A ‘National Emergency Medical Services Network’ to interlink all existing and

l


new ambulances under a common centralized toll free number will a so be formulated. The minister of road, transport and highways, expert committee from the AIIMS, oHFW and Automotive Research Association of India have come together for the urpose of finalizing the draft code which is soon going to be implemented. Mp Verification exercise has led to collection of faulty HIV/AIDS reagents All the invalid 1178 HIV/Aids reagents SD Bioline have been returned to the Medical Stores Department that were to get expired in August 2013. The return was soon followed by quality alert by the World Health Organisation and ordering of new kits.

l f v Proper disposa o the in alid HIV/Aids reagents are yet to be carried out by the government. The deficiency in the kit was observed before it was put to use. The government announced that although it had to return so many kits, it faced no deficiency because t had stock of extra valid HIV/Aids testing kits which enabled the exercise to ontinue. ic J&K focuses on rationalisation of drug use In view of achieving balanced growth in the state pharmaceutical sector and rationalisation of drug use in the state, the Jammu and Kashmir state cabinet has decided on a new drug policy. The policy has decided to procure only essential branded drugs approved by the State Drug Committee. The selection of drugs would also be based taking into account the demand, lead time, transportation and emergency needs. The policy has been specifically designed with an aim to upgrade the healthcare status of the people. The committee also aims to strengthen the Food and Drug Control rganisation and Drug Testing Laboratories of the state and ensure patients receive edicines conveniently and appropriately.

Om Karunya Community Pharmacy to bring relief to common people of Kerala Kerala State Medical Services Corporation Ltd. (KSMSCL) has launched its first Karunya Community Pharmacy in Medical College Hospital premises in Thiruvananthapuram. The second outlet will be opened soon at Kallara Punchayath in the village of Nedumangadu Taluk, 40 km away from Trivandrum Central Railway Station. The government initiated the project to provide common people branded

rugs prescription d at 20%‐60% discounted price. The pharmacies will be controlled and operated by the State Medical Services Corporation. This happens to be the 3rd such initiative by the government in the field of retail pharmacy. The first such initiative was taken up in Chitodgadh district in Rajasthan which was soon followed by Andhra Pradesh Medical Services Corporation (APMSC)

that started the Jeevandhara Pharmacies. The APMSC is operated by local women’s elf help groups, Lion’s Clubs and Rotary Clubs unlike the recently launched Karunya ommunity Pharmacy.


sC BSM organised by Pharmexcil to boost export of medical devices The growing potential of the Indian medical devices market has encouraged Pharmaceuticals Export Promotion Council of India (Pharmexcil) to organise a Global Business Meet on Medical Devices and Surgicals. It will be high profile Buyer‐Seller Meet (BSM) that would help attract investments for the market. The meet has been especially organised in the periphery of the Indian Medical Devices & Plastic

a 3 Disposables Industry 2012 nnual meet from 2 rd‐24th March, 2012 at Ahmedabad Management Association to ensure maximum exposure to businessmen. Pharmexcil’s participation in the event will provide the organisation a perfect pportunity in knowledge sharing session and wide scope of networking and artnerships. op Drug pricing to go through serious change The Health Ministry of India has recommended the pricing of essential drugs to be based on either the average price of 3 cheapest brands available or government’s bulk procurement price. This happens to be a clear rejection of the National Pharmaceuticals Pricing Policy formulated by the Department of Pharmaceuticals in last October to make essential rugs cheaper. It had also suggested a cap on price of 348 essential drugs and its ormulations at the average price of 3 of the highest branded drugs. df Bihar Government and Care India efforts to raise healthcare standards of Bihar women A mini skill laboratory has been commenced assisted by a mobile training team in Alauli Primary Health Centre located in Khagaria district of Bihar. The initiative raised by the principal secretary of Health and Family Welfare of the Bihar. The fulfillment of the initiative however was the outcome of the joint effort by Government of Bihar, State Health Society of Bihar and widely networked women relief organisation Care India. The effort has been undertaken for the sole purpose of reducing the newborn, infant and maternal mortality rate. The mobile training team will provide adequate training o medical staff of Alauli to improve quality of maternal and child care by using dvanced but cost effective technology. ta Union Health Ministry addresses proposal to the Finance Ministry for raising budget allocation for the sector The Indian Health Ministry is making a strong move by forwarding proposals to be included in the Union Budget. It has addressed a proposal to increase the budget allocated for requisite manpower and infrastructure. The Health Ministry has also


forwarded its request for setting up of medical device testing laboratories each worth INR 400 mn in order to strengthen regulatory framework for medical devices sector. It has also made plea for exemption of customs duty of life‐saving medical devices and consumables used with devices in special life‐saving treatment procedures. A waiver in the customs has also been requested for radiopharmaceuticals used in diagnostic imaging and scanning. Added to these, on behalf of the industry, the Health Ministry has sought for rationalisation of duty exemptions to bring in clarity, as different medical devices have different level of exemptions under various entries in different notifications. Lastly, it has also suggested reduction in excise duty from current 10% o nil on locally purchased input for the manufacture of medical equipment, spares nd accessories. ta News Update

Expansion Plans Apollo expands to Kerala Apollo hospital is pursuing a green field project in Kochi worth INR 1500 mn. Apollo group plans to build a multi speciality hospital with a minimum capacity of 100 beds that is expected to escalate to 300 beds. The group is in the process of setting up 13 new hospitals with ongoing expansion of 4 of its existing facilities. The new projects undertaken are expected to raise approximately 2860 hospital beds by FY15 and the cost being incurred on the ngoing projects is INR 16.46 bn. This includes four Reach hospitals, three super pecialty hospitals in Mumbai and one super specialty hospital in Patna. os Opto Circuits (India) partners with German aircraft interior manufacturer Opto Circuits (India) subsidiary Cardiac Science Corporation will soon be supplying Cardiac Science Automated External Defibrillators (AEDs) to Germany based aircraft interior manufacturer Innovint Aircraft Interior GmbH. The AED will be distributed on aircrafts worldwide by Innovint. AED is a portable device that automatically diagnoses cardiac irregularities and also treats them through defibrillation. Medical equipments manufactured by Opto Circuits are time tested and exceed the rigorous standards common in the aerospace industry for emergency equipment and hence has been chosen by Innovint. Pathfinder Health India launches its 3rd medical clinic Delhi based Pathfinder Health India has launched its 3rd clinic at Greater Kailash in Delhi. Pathfinder has launched clinics in quick succession due to the overwhelming response it received after its first clinic launch. The first came up at Janakpuri in Oct 2011 which was followed by the 2nd clinic at Vikaspuri in Dec 2011. Their other proposed locations include Defense Colony, East of Kailash, Rohini, NFC and


Karolbagh. Apart from Delhi, Pathfinder is also eager to set up its clinics in other parts of the country as well. Pathfinder was founded as an alliance of social entrepreneurs of UK and India. It aims in providing low cost but high quality healthcare service for people. Pathfinder is trying to raise awareness about the significance of Family Medicine wherein family doctors can ensure personalized care for each patient and his family that will also enable early detection and treatment of family diseases. Lupin Ltd. plans big investment in Pune Lupin Limited is planning to invest INR 997 mn for a new manufacturing facility in Pune. The unit is being planned to be set up in 2 years time. The manufacturing unit

shas been conceived for the purpo e of production capacity expansion of biotech products. The Mumbai based pharmaceutical company currently has over 7 newly discovered molecules covering oncology and inflammation segments. Out of them 3 are already ndergoing clinical trials. Lupin is also set to launch a cancer drug by next year which s soon to go for the 3rd stage clinical trial. ui Covidien sets up its 1st R&D unit in India US based Covidien inaugurated its 25th R&D centre in India that stretches over 40,000 square foot area in Hyderabad. The R&D unit has been named Covidien India Engineering Centre (CIEC). Presently, employing 30 engineers and staff of their global

i a o operations team, t hopes to employ n additional 350 professi nals in the span of next 2 years. Covidien having planned to raise its present percentage share of revenue on R&D from 5% to 6% was eager to invest in India. Indian healthcare devices market has been experiencing a 15 % year‐on‐year growth that led to Covidien’s interest. Covidien aims to take advantage of the talented Indian engineers for manufacturing edical products demanded by Indian local market, focus on development and nnovation of new products and ensure speedy product delivery. mi Sun Pharma issues fresh shares for conducting clinical trial of Paclitaxel Sun Pharma Advanced Research Company (SPARC) in order to conduct clinical trials in the USA pharmaceutical market has planned to issue fresh shares worth INR 2000 mn. The fund raised will be used for ensuring safety and efficiency of a newly developed cancer injection called Paclitaxel and for the first phase of tests on the effectiveness of a new patient‐friendly administration protocol for Paclitaxel in US. Apart from that, a large part of the fund would be used for repayment of the company’s debts. Paclitaxel Injection Concentrate for Nano dispersion (PICN) is being developed with he idea of it being a safer cancer treatment that requires shorter infusion time and elivers higher concentration of drug in tumour tissues. td Biocon expands production base to Southeast Asia

Bangalore based biotechnology firm Biocon has planned an expansion to Southeast Asia in Johor state of Malaysia. Biocon will set up an insulin plant that would be approximately worth INR 7865.6 mn and is expected to start its operation by 2014.


Biocon is currently conducting clinical trials for insulin with a partner based in Thailand. Biocon known for manufacturing affordable pharmaceutical products intends to make Southeast Asia a lucrative production base that will eventually benefit the global market as well. Bactiguard and Cadila collaboration to bring the Swedish company products to India Sweden based company Bactiguard renowned for its hospital‐acquired infections solutions has entered into an exclusive deal with India based healthcare manufacturing group Cadila Pharmaceuticals. Cadila will market and sell entire range of Bactiguard products in India. The finalization of the deal will take place at the Swedish Ambassador's residence. The collaboration took place with the effort of Dr.C.B. Sanjeevi of Karolinska Institute and Invest Sweden, along with Swedish EKN, Export Credit Guarantee Authority. Industry Expert Speak RGSTC in plans to set up Biomedical Engineering and Technology Centre Prakash Dolas, Adviser to the Commission and CentreinCharge, RGSTC “It is an upcoming field and has huge scope for R&D. The prosthesis, implants imported are not fully suited for Indian physique and pocket except for elite class. Chitra valve developed by Sree Chitra Tirunal Institute for Medical Sciences and echnology (SCTIMST), Trivandrum and manufactured by TTK Healthcare is an ideal ndian example. The centre would concentrate on developing such devices.” TI Jammu and Kashmir to have a new drug policy Sham Lal Sharma, J&K State Minister for Health “J‐K will now have a new drug policy based on the rationalisation of the use of drugs. t was given a nod by state cabinet yesterday. The policy has been formulated with an im to upgrade the health care status of Jammu and Kashmir.” Ia IIL to develop vaccination for Chikungunya and JEV KV Balasubramaniam, Managing Director, IIL “Currently, no vaccine is available for chikungunya anywhere in the world. IIL is developing a vaccine for this disease using a virus strain isolated by a laboratory in the USA. For Japanese encephalitis virus (JEV) infection, IIL is developing a better and safer vaccine by producing the virus in cell culture, instead of using mouse brain for

rowing the virus, which the current vaccine manufacturers do. The inactivated JEV accine is thus a safer vaccine.”


gv Karunya Community Pharmacy to bring relief to common people of Kerela Adoor Prakash, the State Health Minister “People can buy all the drugs from the counter on 20‐60 % discount of the MRP. We are planning to sell all kinds of drugs through these community pharmacies. Shortly more pharmacies will be inaugurated in all district hospitals, taluk hospitals and in elected panchayats. There are very big differences in the prices of drugs sold through arunya pharmacy and through other shops outside”

sK Nanophotomedicine soon to become an effective remedy for cancer – Dr. Manzoor Koyakutty, head of Amrita Centre for Nanosciences and Molecular Medicine research team “We have developed a nanomedicine that is a non‐toxic and biocompatible polymer. It will be a major alternative to radiation therapy which causes a lot of harmful side‐effects to the body. The medicine given during radiation therapy costs around Rs 2‐2.5 lakh and spreads all over the body, damaging healthy cells too. But this is a targeted medicine and 85‐95% of it will attach itself around the tumours. he safety trials will be completed by next year and we hope to start human trials by 014.” T2 Transactions (December 2011 – February 2012)

Date Buyer Target Deal Size (INR mn) % stake Deal Status

Type of Transaction

14th Feb 2012

Fidelity Growth Partners India

Aptuit Laurus Pvt. Ltd.

2000 NA Planned Private Equity

6th Feb 2012

Nova Medical Centers Pvt. Ltd. Helios Hospitals ‐ 100% Completed M&A

1st Feb 2012

Fortis Healthcare (India) Ltd.

RadLink‐Asia Pte Ltd.

2510 85% Completed M&A

1 8th Jan2012

Olympus Capital

DM Healthcare 5000 NA Planned Private Equity

1 6th Jan2012 Life Healthcare

Max Healthcare Institute Ltd. 5165 26% Planned M&A

Date Buyer Target Deal Size (INR mn)

% stake Deal Status Type of

Transaction

12th Jan 2012

Fortis Healthcare (India) Ltd

Fortis Healthcare International

34885 100% Completed M&A

2 nd Dec2011 Vivimed Labs Uquifa 2840 100% Completed

M&A

Annual Financial Results – Revenue (INR mn) – Major Healthcare Companies

Companies FY ’08 FY ’09 FY ’10 FY ’11

Abott India Ltd. 6 ,763.60 7,822.70 9,406.60 9 ,373.90

Advanced Micronic Devices Ltd. 524.21 585.812 660.023 718.23

Ajanta Pharma Ltd. 3,093.70 3,493.40 4,091.40 5,048.70

Albert David Ltd 1,596.42 1,851.75 2,029.58 2,184.95

Alembic Ltd. 1 0,075.76 1 1,190.28 1 1,399.17 2,007.84

Amrutanjan Health Care Ltd. 744.317 906.738 897.789 1,054.09

Apollo Hospitals Enterprise Ltd. 12,163.50 16,142.10 20,264.70 26,053.50

Biocon Ltd. 10,738.90 16,492.50 23,932.70 27,947.70


Blue Star Ltd. 22,215.90 2 5,026.20 2 5,249.70 2 9,760.90

BPL Ltd. 2,090.50 1,293.10 1,185.30 2,296.70

Cadila Healthcare Ltd. 23,063.00 29,066.00 35,780.00 44,671.00

Cipla Ltd. 42,602.70 52,876.20 56,704.00 63,850.70


Claris Lifesciences Ltd. 7,521.60 7,435.30 7,523.40 NA

Dabur India Ltd. 23,657.20 28,122.40 3 3,958.00 40,817.40

Divi's Laboratories Ltd. 10,387.00 11,849.50 9,499.20 13,137.00

Dr. Reddy’s Laboratories (DRL) 49,448.00 6 9,441.00 7 0,277.00 7 4,693.00

Elder Pharmaceuticals Ltd. 5,512.00 6,242.30 7,284.10 9,648.50

FDC Ltd. 4,964.40 5,909.00 6,340.10 7,103.30

Fortis Healthcare (India) Ltd. 5,071.00 6,305.90 9,380.60 1 4,829.70

Fresenius Kabi Oncology Ltd. 2,688.00 3,257.20 4,884.80 5,2 0 55.6

GlaxoSmithKline Pharmaceuticals Ltd.

17,032.80 19,179.80 21,608.50 NA

Glenmark Pharmaceuticals Ltd. 19,800.00 21,241.20 25,291.30 29,490.70

HCL Infosystems Ltd. 1 22,445.40 1 22,524.10 1 20,498.20 1 14,199.20

Hikal Ltd. 4,866.60 5,728.70 5,389.50 5,023.00

Infosys Ltd. 1 66,987.80 2 36,369.80 2 15,747.60 269 .60 ,277

Intas Pharmaceuticals Ltd. 9,236.70 11,266.20 16,172.30 NA

Jubilant life Sciences Ltd. 25,017.60 3 5,491.00 3 8,047.80 3 4,484.40

Kopran Ltd. 1,297.09 1,186.33 1,643.59 1,947.75

Larsen & Toubro Ltd. 292,118.60 401,949.60 435,285.30 515,624.40


Lupin Ltd. 2 8,708.50 3 8,508.30 4 8,318.10 5 7,851.90

Maestros Mediline Systems Ltd. 349.418 295.262 304.853 425.648

Morepen Laboratories Ltd. 1,477.70 1,854.80 2,121.80 2,293.40

Nestle India 43,252.20 51,395.50 62,609.40 5,340.80


Opto Circuits (India) Ltd. 4,680.80 8,185.20 1 0,775.80 15,855.60

Panacea Biotec Ltd. 8,439.50 7,921.80 9,066.70 1 1,573.50

Pfizer Ltd. 7,036.10 7944.1* NA 9,326.10

Piramal Healthcare Ltd. 28,672.90 32,478.20 36,276.30 25,1 .70 57

Plethico Pharmaceuticals Ltd. 9,845.50 12,459.00 15,121.10 NA

Ranbaxy Laboratories Ltd. 74,1 .00 40 75,9 .40 70 8 9,607.70 87315.9*

Regency Hospital Ltd. NA NA 4 00.476 52 1 2.04

Shree Pacetronix Ltd. 58.355 59.139 62.078 NA

Siemens Ltd. 9 6,858.40 9 3,070.20 9 6,272.40 11 0 9,718.1

Span Diagnostics Ltd. 605.742 675.954 802.615 84 3 0.6

Strides Arcolab Ltd 10,310.00 13,234.80 17,367.30 NA

Sun Pharmaceuticals Industries Ltd. 33,5 .30 65 4 2,723.00 3 8,086.30 57,2 .30 14

Super Religare Laboratories Ltd. NA 1,380.58 1,693.57 NA

Tata Consultancy Services Ltd. 2 28,001.90 2 81,539.70 3 04,885.10 3 79,620.20

Torrent Pharmaceuticals Ltd 13,548.50 1 6,306.60 1 9,160.40 2 2,264.80

Twilight Litaka Pharma Ltd. 2,951.70 3,708.40 4 ,924.10 6,709.20

Vimta Labs Ltd 766.939 816.032 8 68.02 957.013

Vista Pharmaceuticals 10.244 18.231 8.014 56.745


Wipro Ltd. 1 97,428.00 2 55,837.00 2 71,115.00 3 09,535.00

Wockhardt Ltd. 35,998.60 36294.4* 36,4 .60 77 37,6 .50 33

Zandu Realty Ltd. 1,687.50 877.461 NA NA

Quarterly Financial Results – Revenue (INR mn) – Major Healthcare Companies

Companies JanMar 2011

AprJun 2011

JulSep 2011

OctDec 2011

Abott India Ltd. 2,336.70 3,514.20 3,968.90 N.A.

Advanced Micronic Devices Ltd. 27 1 7.38 114.251 12 9 9.99 N.A.

Ajanta Pharma Ltd. N.A. 1,273.10 N.A. 1,639.00

Albert David Ltd. 476.737 59 1 1.70 6 32.71

Alembic Ltd. ‐8, 16 061. N.A. 260.7 281.00

Amrutanjan Health Care Ltd. N.A. N.A. N.A. 363.639

Apollo Hospitals Enterprise Ltd. N.A. 6,410.10 N.A. 7,147.50

Biocon Ltd. N.A. 4,416.80 5,084.40 5,171.90

Blue Star Ltd. N.A. N.A. N.A. 5 ,896.90

BPL Ltd. N.A. 190.4 N.A. 227.6

Cadila Healthcare Ltd. 11, 0 711.4 11,735.10 12 0 ,196.4 13,524.60

Cipla Ltd. N.A. 15,91 4.20 N.A. 17, 00 580.

Claris Lifesciences Ltd. 1,566.50 1,916.70 2,040.90 N.A.

Dabur India Ltd. 11,12 5.10 12,04 5.80 12 0 ,623.3 1 4,526.80

Divi's Laboratories Ltd. 4,852.00 3,585.50 N.A. 4,174.20

Dr. Reddy’s Laboratories (DRL) 20,173.00 19,783.00 22,678.00 27,692.00


Elder Pharmaceuticals Ltd. 3,0 0 83.6 2,996.60 3,3 0 10.8 2,569.60

FDC Ltd. N.A. 1,823.20 N.A. 1,636.60

Fortis Healthcare (India) Ltd. 4,2 0 69.7 4,783.40 5,988.50 5,964.90

Fresenius Kabi Oncology Ltd. N.A. N.A. N.A. 1,283.20


AprJun 2011

JulSep 2011

OctDec 2011

GlaxoSmithKline Pharmaceuticals Ltd.

N.A. 5,615.40 6,146.20 N.A.


HCL Infosystems Ltd. 27, 0 300.1 2 6,154.00 27 0 ,875.7 2 6,736.80

Hikal Ltd. N.A. 1,428.00 N.A. 1,854.80

Infosys Ltd. 71,409.10 74,69 3.70 85,685.00 95,835.40

Jubilant life Sciences Ltd. 9,053.80 9,442.90 10 80 ,480. 10 0 ,871.7

Kopran Ltd. N.A. N.A. N.A. 497.4

Larsen & Toubro Ltd. N.A. N.A. N.A. 1 39,985.80

Lupin Ltd. 15 0 ,067.4 1 5,677.40 17 90 ,723. 18, .30 189

Maestros Mediline Systems Ltd. N.A. 1 30.265 N.A. N.A.

Morepen Laboratories Ltd. 571.9 602.1 N.A. 711.1

Nestle India 18,09 9.90 17,63 0.50 19,63 1.00 1 9,627.00

Opto Circuits (India) Ltd. 5,4 0 45.5 5,208.20 5,6 0 20.4 6,112.90

Panacea Biotec Ltd. N.A. 2,209.90 N.A. 1,551.60

Pfizer Ltd. N.A. 2,418.70 2,718.20 2,518.80

Piramal Healthcare Ltd. 5,470.10 4,350.00 4,775.80 5,5 0 18.3

Plethico Pharmaceuticals Ltd. 3,538.50 4,543.10 4,119.50 N.A.

Ranbaxy Laboratories Ltd. N.A. N.A. 87315.9 N.A.


Regency Hospital Ltd. 522.041 N.A. N.A. 568.552

Span Diagnostics Ltd. 211.725 139.433 N.A. 11 7 8.95

Strides Arcolab Ltd 4,874.80 5,812.50 7,693.10 N.A.

Sun Pharmaceuticals Industries Ltd.

13,505.90 16,357.20 18,946.00 21,451.30


AprJun 2011

JulSep 2011

OctDec 2011

Tata Consultancy Services Ltd. 1 04,020.10 1 07,798.50 1 10,028.30 1 34,142.80

Torrent Pharmaceuticals Ltd 5,943.20 6,133.90 6,5 0 77.6 6,755.40

Twilight Litaka Pharma Ltd. 1,758.90 1,835.60 N.A. 1,867.20

Vimta Labs Ltd 2 48.687 2 45.438 20 3 2.42 20 5 1.51

Vista Pharmaceuticals 26.132 11.461 N.A. N.A.

Wipro Ltd. 82,45 5.00 84,673.00 89,769.00 98,488.00

Wockhardt Ltd. 9,508.40 10,532.10 11,105.30 12,086.70

Annual Financial Results – Income (INR mn)

Companies F Y ’08 F Y ’09 F Y ’10 F Y ’11

Abott India Ltd. 628.6 775.1 753* 562.5

Advanced Micronic Devices Ltd. 1 0.445 14.948 2.585 1 7.386

Ajanta Pharma Ltd. 218.8 254.3 340 507.1

Albert David Ltd 73.397 75.263 102.74 108.458

Alembic Ltd. 1 ,121.93 108.17 395.378 ‐129.019

Amrutanjan Health Care Ltd. 50.27 923.94 114.717 102.119

Apollo Hospitals Enterprise Ltd. 771.6 1,024.90 1,375.70 1,839.20


Biocon Ltd. 4,639.10 931.2 2,932.40 3,675.20

Blue Star Ltd. 1,740.90 1,8 0 02.9 2, 0 114.9 1 ,609.70

BPL Ltd. ‐1,456.90 39.4 ‐33.7 758.4

Cadila Healthcare Ltd. 2,576.00 3,031.00 5,051.00 7,110.00


Cipla Ltd. 7,010.40 7,710.20 10,825.90 9,895.70

Claris Lifesciences Ltd. 1,079.00 1,303.70 1,414.40 N.A.

Dabur India Ltd. 3,331.30 3,905.00 5,010.80 5,685.70

Divi's Laboratories Ltd. 3,476.00 4,166.40 3,403.40 4,292.70

Dr. Reddy’s Laboratories (DRL) 3,846.00 ‐5,168.00 1,068.00 11,040.00

Elder Pharmaceuticals Ltd. 697.1 608.3 495 642.2

FDC Ltd. 631.7 862.1 1,491.30 1,508.90

Fortis Healthcare (India) Ltd. ‐368.9 208.2 694.8 1,243.60

Fresenius Kabi Oncology Ltd. 985.9 ‐1,460.20 ‐333.6 160.1

GlaxoSmithKline Pharmaceuticals Ltd. 5,910.90 5,078.60 5,605.70 N.A.


HCL Infosystems Ltd. 3,025.80 2,399.50 2,423.80 1,681.90

Hikal Ltd. 477.6 405 72.9 370.2


Infosys Ltd. 46,505.50 64,934.50 58,966.80 66,817.90

Intas Pharmaceuticals Ltd. 763.3 923.2 2,058.20 N.A.

Jubilant life Sciences Ltd. 4,004.90 2,831.80 4,214.60 2,297.20


Kopran Ltd. 72.824 ‐137.893 68.993 45.344

Larsen & Toubro Ltd. 23,253.60 37,894.60 54,507.40 44,561.70

Lupin Ltd. 4,082.50 5,015.40 6,816.30 8,625.50

Maestros Mediline Systems Ltd. 5.189 2.547 5.976 36.701

Morepen Laboratories Ltd. ‐548.6 ‐417.6 ‐62.2 ‐469.4

Nestle India 6,550.00 8,186.60 N.A. N.A.

Opto Circuits (India) Ltd. 1,306.60 2,087.30 2,603.00 3,672.50

Panacea Biotec Ltd. 1,289.80 ‐654.8 817.2 1,446.70

Pfizer Ltd. 2,995.70 1371.2* N.A. 1,697.60

Piramal Healthcare Ltd. 3,337.80 3,162.50 4,819.00 128,833.60

Plethico Pharmaceuticals Ltd. 1,233.60 2,169.30 2,444.00 N.A.

Ranbaxy Laboratories Ltd. ‐9,512.10 2,964.90 14,967.50 ‐144.4

Regency Hospital Ltd. N.A. N.A. 11.34 22.342


Shree Pacetronix Ltd. 2.663 1.586 1.11 N.A.

Siemens Ltd. 5,995.50 7,046.00 7,577.70 8,677.50

Span Diagnostics Ltd. 27.258 12.588 54.534 54.897


Strides Arcolab Ltd 1,079.60 1,096.80 1,224.50 N.A.

Sun Pharmaceuticals Industries Ltd. 14,869.00 18,177.30 13,510.80 18,160.60

Super Religare Laboratories Ltd. N.A. ‐36.48 ‐336.06 N.A.

Tata Consultancy Services Ltd. 50,260.20 52,564.20 70,006.40 90,680.40

Torrent Pharmaceuticals Ltd 1,346.80 1,843.70 2,312.00 2,701.70

Twilight Litaka Pharma Ltd. 180.3 219.4 326.3 512.5

Vimta Labs Ltd 62.457 40.443 26.586 ‐46.651

Vista Pharmaceuticals ‐8.846 ‐9.616 ‐13.502 ‐2.922

Wipro Ltd. 32,241.00 38,761.00 45,931.00 52,977.00

Wockhardt Ltd. ‐1,388.60 ‐4355.4*' ‐9,804.20 905.2

Zandu Realty Ltd. 164.83 152.549 13.906 9.144

* denotes a change in financial year

Quarterly Financial Results – Income (INR mn)



AprJun 2011

JulSep 2011

OctDec 2011

Abott India Ltd. 59.4 171 436.3 N.A.

Advanced Micronic Devices Ltd. 8.898 1.673 0.589 N.A.

Ajanta Pharma Ltd. N.A. 125.3 N.A. 185.1


AprJun 2011

JulSep 2011

OctDec 2011

Albert David Ltd 3.533 9.923 4 4.553 N.A.

Alembic Ltd. ‐76 9 9.91 N.A. ‐ 17.9 ‐44.4

Amrutanjan Health Care Ltd. N.A. N.A. N.A. 43.17 2

Apollo Hospitals Enterprise Ltd. N.A. 512.7 N.A. 646.5

Biocon Ltd. N.A. 700.5 857 848.50

Blue Star Ltd. N.A. N . .A N.A. ‐327.6

BPL Ltd. N.A. ‐5 N.A. 215.6

Cadila Healthcare Ltd. 1,7 0 89.7 2,298.20 1,0 0 26.8 1,492.10

Cipla Ltd. N.A. 2 ,533.40 N.A. 2,6 0 99.1

Claris Lifesciences Ltd. 198.9 377.2 340.1 N.A.

Dabur India Ltd. 1,470.10 1,279.20 1,7 0 38.5 1,718.20

Divi's Laboratories Ltd. 1,751.90 1,025.90 N.A. 1,225.50

Dr. Reddy’s Laboratories (DRL) 3 ,345.00 2 ,627.00 3 ,078.00 5 ,131.00

Elder Pharmaceuticals Ltd. 180.3 201.2 193.5 227.1

FDC Ltd. N.A. 344 N.A. 329

Fortis Healthcare (India) Ltd. 294.1 140.3 ‐125.9 292.6

Fresenius Kabi Oncology Ltd. N.A. N.A. N.A. 14

GlaxoSmithKline Pharmaceuticals Ltd. N.A. 1,475.40 1,458.60 N.A.


Glenmark Pharmaceuticals Ltd. 764.8 2 ,101.10 558.6 461.20

HCL Infosystems Ltd. 532.8 114.8 121.5 349.2 0

Hikal Ltd. N.A. 145 N.A. 130.4

Infosys Ltd. 17,919.10 17,164.80 20,169.80 24,303.80


AprJun 2011

JulSep 2011

OctDec 2011

Jubilant life Sciences Ltd. 617.2 771.2 793.6 ‐7 83.90

Kopran Ltd. N.A. N.A. N.A. 19.1

Larsen & Toubro Ltd. N.A. N.A. N.A. 9,915.50

Lupin Ltd. 2,2 0 72.0 2 ,100.80 2,668.70 2,350.60

Maestros Mediline Systems Ltd. N.A. 9.018 N.A. N.A.

Morepen Laboratories Ltd. ‐111.5 ‐131.3 ‐90.6 N.A.

Nestle India 2,557.10 2,138.30 2,611.80 2,308.30

Opto Circuits (India) Ltd. 1,1 0 11.0 1 ,163.90 1,2 0 10.6 1 ,250.80

Panacea Biotec Ltd. N.A. 167.2 N.A. ‐717.2

Pfizer Ltd. N.A. 412.4 469.9 482.8

Piramal Healthcare Ltd. 2 ,018.50 892.3 524.3 85.2

Plethico Pharmaceuticals Ltd. 552.5 743.6 385.9 N.A.

Ranbaxy Laboratories Ltd. N.A. N.A. ‐144.4 N.A.

Regency Hospital Ltd. 2 2.342 N.A. N.A. 27.272

Strides Arcolab Ltd 16.66 1 5.799 N.A. ‐2 8 7.84

Sun Pharmaceuticals Industries Ltd.

407.1 688.9 464.7 N.A.

Tata Consultancy Services Ltd. 26 0 ,229.3 23,76 7.00 21 0 ,064.7 28 0 ,027.7

Torrent Pharmaceuticals Ltd 428.5 1,025.20 999.9 831.8


Twilight Litaka Pharma Ltd. 108.4 128.2 N.A. 93.8

Vimta Labs Ltd ‐ 33.881 ‐ 14.438 ‐3 3 3.97 ‐3 2 7.70

Vista Pharmaceuticals 0.118 ‐2.687 N.A. N.A.

Wipro Ltd. 13,755.00 13,349.00 13,009.00 14,564.00


AprJun 2011

JulSep 2011

OctDec 2011

Wockhardt Ltd. 1 ,618.30 1 ,939.60 1 ,275.80 2 ,128.10

Zandu Realty Ltd. 0.823 1.931 3.205 11.675

Events Calendar

MEDICAL FAIR INDIA 2012 Date: 2nd March – 4th March 2012 Venue: Goa Medical College Organiser: Indian Academy of Cytologists with European Federation of Cytology Societies and International Academy of Cytology

IN RESSDIA HEALTHCARE CONG

Date: 20 2012 th March – 21

Organiser

st March Venue: Grand Hyatt, Mumbai

: InnovWebsite:

eta www.indiahealthcarecongress.in

Contact ID: h noveta.in Contact Person: Neha Chopra

ealthcarecongress@inContact No.: +91 (0) 80 3294 7444

GLOBAL BUSINESS MEET ON MEDICAL DEVICES & SURG

Date: 23

ICALS

rd March – 24th March 2012 Venue: Ahmedabad Management Association Organiser port Promotion Council of

: Pharmaceuticals Ex Ind

Website: ia (Pharmexcil) w.pharmexcil.orgww

Contact No.: 040‐23735462/66


http://www.indiahealthcarecongress.in/

Research on India (ROI) is a leading source for market research on various sectors in ndia that offers premium research content from worldwide publishers of market Iresearch reports. For any queries, contact us: W: https://www.researchonindia.com el: India (Toll Free): 1800 102 1133; Inmail: TE

ternational: +91 (33) 4027 6214/5 [email protected]

Connect with Us

Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document


http://www.facebook.com/researchonindia

https://twitter.com/ResearchOnIndia

http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

research on india_healthcare sector in india monthly update_february 2012

Documents

ovarian cancer

newmanufacturing facility

blood cells

dose proportionality

coughcoldandnutra biosys

successful early stage

multiple dosestudies

celonspecializes inoncology